Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving…
Afrigen Biologics and Vaccines: A Catalyst in mRNA Technology and LMIC Capacity Strengthening
Afrigen Biologics and Vaccines embodies the spirit of equitable healthcare innovation, scientific advancement, and regional…
The Biggest Challenge to Ending TB is not Scientific
Statement from TB Alliance on World TB Day For most of human history, tuberculosis (TB)…
PeerLINC Recognizes One Year of Transforming Drug-Resistant TB Treatment Through Faster, More Easily Accessible Technical Assistance
The PeerLINC Knowledge Hub, an innovative peer-to-peer initiative that connects experts from countries that rapidly…
Mel Spigelman on the future of TB treatment and the evolution of TB Alliance
2025 marks the 25th anniversary of TB Alliance. Throughout the year, we are sitting down…
TB Alliance Works With Stop TB Canada, Viatris, and Local Physicians to Speed Pretomanid Access in Canada
Stop TB Canada has announced a streamlined process to speed up the availability of pretomanid,…
Ariel Pablos-Mendez on the past, present, and future of TB research and the TB Alliance
February 8th marks the 25th anniversary of the signing of the Cape Town Declaration, which…
Funding for TB and Neglected Disease Research Must Increase to Realize Promise of New Technologies
Statement from TB Alliance on release of the G-FINDER 2024 Neglected Disease R&D Report NEW…
Historically Successful Global Access Campaign for Pretomanid and BPaL-based Regimens Continues with Major Milestones in BRICS Countries
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based…